Akinori Minato
Overview
Explore the profile of Akinori Minato including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsubonuma Y, Nagata Y, Higashijima K, Minato A, Tomisaki I, Fujimoto N
Cureus
. 2025 Feb;
17(1):e77948.
PMID: 39996187
Recently, enfortumab vedotin has emerged as a promising treatment option for metastatic urothelial carcinoma. Although it does not require dosage adjustments in patients with renal failure, its safety and efficacy,...
2.
Jojima K, Minato A, Noguchi H, Tsuda Y, Fujimoto N
Cancer Diagn Progn
. 2025 Jan;
5(1):122-126.
PMID: 39758247
Background/aim: This study examined the treatment outcomes of radical cystectomy (RC) for micropapillary subtype (MPS) bladder cancer treated at our hospital. Patients And Methods: Histopathological findings of RC specimens collected...
3.
Minato A, Yoshii M, Watanabe S, Moriya R, Kashiwagi E, Fujimoto N
Jpn J Clin Oncol
. 2024 Dec;
PMID: 39709558
Objective: This study aimed to assess the oncological outcomes of the subtype of urothelial carcinoma (SUC), including divergent differentiation and histologic subtype, in comparison with those of pure urothelial carcinoma...
4.
Tomisaki I, Harada M, Sakano S, Terado M, Hamasuna R, Harada S, et al.
Oncol Lett
. 2024 Nov;
28(6):603.
PMID: 39525607
Data on the C-reactive protein (CRP) flare response in patients with metastatic and unresectable urothelial carcinoma (mUC) are limited. The present study aimed to clarify the clinical significance of the...
5.
Minato A, Tomisaki I, Kimuro R, Higashijima K, Harada M, Jojima K, et al.
Nihon Hinyokika Gakkai Zasshi
. 2024 Oct;
114(4):99-107.
PMID: 39428549
(Objective) The study aimed to retrospectively evaluate the therapeutic effects of adjuvant chemotherapy (AC) in patients following radical cystectomy (RC) in locally advanced bladder cancer. (Methods) A single-center-derived database registered...
6.
Nagata Y, Minato A, Aono H, Kimuro R, Higashijima K, Tomisaki I, et al.
Int J Mol Sci
. 2024 Oct;
25(19).
PMID: 39408678
Locally advanced or metastatic urothelial carcinoma is a genomically and molecularly heterogeneous disease associated with various clinical outcomes. We aimed to evaluate the association between the status of p53/FGFR3 expression...
7.
Fujimoto N, Nagata Y, Shiota M, Minato A, Tomisaki I, Harada K, et al.
In Vivo
. 2024 Aug;
38(5):2328-2334.
PMID: 39187338
Background/aim: In patients with metastatic castration-sensitive prostate cancer (mCSPC), upfront treatment intensification with the addition of new hormonal agents and/or docetaxel to androgen deprivation therapy (ADT) is recommended. However, this...
8.
Minato A, Furubayashi N, Tomoda T, Hori Y, Kiyoshima K, Negishi T, et al.
Transl Androl Urol
. 2024 Aug;
13(7):1118-1126.
PMID: 39100842
Background: The subtype of urothelial carcinoma (SUC) has been known to possess morphological diversity for histologic subtype or divergent differentiation. However, the efficacy of avelumab against SUC remains unclear. Therefore,...
9.
Minato A, Furubayashi N, Tomoda T, Masaoka H, Song Y, Hori Y, et al.
Anticancer Res
. 2024 Jul;
44(8):3419-3426.
PMID: 39060065
Background/aim: This study retrospectively evaluated whether enfortumab vedotin (EV) monotherapy is effective as a late-line treatment according to prior treatment type in patients with advanced urothelial carcinoma (UC). Patients And...
10.
Furubayashi N, Minato A, Tomoda T, Masaoka H, Hori Y, Kiyoshima K, et al.
Anticancer Res
. 2024 Jul;
44(8):3409-3417.
PMID: 39060060
Background/aim: The efficacy, safety, and liver toxicity of enfortumab vedotin (EV) for elderly advanced urothelial carcinoma (UC) patients and patients with a poor performance status (PS) are unclear. Patients And...